Physicians

Department / Division
Pediatrics / Pediatrics-Hematology/Oncology

Address
DUMC 102382
Durham, NC 27710

Appointment Telephone
919-684-3401

Office Telephone
919-668-9055

Fax Telephone
919-681-7950

Training

• MD, University of Minnesota Medical School, 2001

Residency

• Pediatrics, University of Michigan Medical Center, 2001-2003

Fellowship

• Pediatric Hematology/Oncology, University of Michigan, 2003-2006

Other Training

• PhD, Biochemistry, Biophysics, and Molecular Biology, University of Minnesota, 1999

Clinical Interests
Advanced treatments for neuroblastoma, pediatric solid tumors, and leukemia

Research Interests
Neuroblastoma is the most common extra-cranial solid tumor of childhood.  Despite advances in the treatment of childhood cancer, outcomes for children with advanced-stage neuroblastoma remain poor.  My basic science research interests are focused on understanding the physiology of the neuroblastoma cell and what it does to circumvent the effects of chemotherapy.  Additionally, I am interested in translational research in neuroblastoma.  We have open trials for therapeutic MIBG and anti-GD2 antibody treatment for neuroblastoma.  Clinically, I am involved in the treatment of childhood malignancies including neuroblasotma, soft tissue sarcomas, and leukemia.  Additionally, I have an interest in the management of vascular malformations, such as hemangioma.

Industry Relationships and Collaborations (What's this?)

This physician (or a member of their immediate family) has a working relationship (i.e. consulting, research, and/or educational services) with the companies listed below. These relations have been reported to the health system leadership and, when appropriate, management plans are in place to address potential conflicts.

• Baxter Healthcare

Representative Publications
Armstrong, MB, “Proteasome Inhibition: Thinking Outside the Box,” Clin Med: Therap, 1:1599-1606, 2009. (2009)

Navid, F, Armstrong MB, Barfield, RC, “Immune therapies in neuroblastoma,” Cancer Biol Ther, 8:1-9, 2009. (2009)

Armstrong MB, Schumacher KR, Mody R, Yanik GA, Opipari AW Jr, Castle VP. Bortezomib as a therapeutic candidate for neuroblastoma. J Exp Ther Oncol. 2008;7(2):135-45. (2008) Abstract

Armstrong MB, Bian X, Liu Y, Subramanian C, Ratanaproeksa AB, Shao F, Yu VC, Kwok RP, Opipari AW Jr, Castle VP. Signaling from p53 to NF-kappaB determines the chemotherapy responsiveness of neuroblastoma. Neoplasia. 2006 Nov;8(11):967-77. (2006) Abstract

Armstrong MB, Robertson PL, Castle VP. Delayed, recurrent opsoclonus-myoclonus syndrome responding to plasmapheresis. Pediatr Neurol. 2005 Nov;33(5):365-7. (2005) Abstract